| Title |
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
|
|---|---|
| Published in |
Advances in Therapy, June 2016
|
| DOI | 10.1007/s12325-016-0345-2 |
| Pubmed ID | |
| Authors |
Kazuyoshi Otake, Yuuichi Sakurai, Haruyuki Nishida, Hideo Fukui, Yoshihiko Tagawa, Hitomi Yamasaki, Masatoshi Karashima, Keiichi Otsuka, Nobuhiro Inatomi |
| Abstract |
Proton pump inhibitors (PPIs) are widely prescribed as first-line therapy for the treatment of acid-related diseases, such as peptic ulcers and gastro-esophageal reflux disease, and for the eradication of Helicobacter pylori. However, the therapeutic efficacy of conventional PPIs is considered limited because: (1) they are unstable under acidic conditions and require an enteric-coated formulation in clinical use; (2) they show high interindividual variability in pharmacokinetics due to genetic polymorphisms of cytochrome P450 (CYP) 2C19 metabolism; (3) they have a relatively slow onset of pharmacological action and may require several doses to achieve optimal acid suppression and symptom relief; and (4) they often do not provide stable suppression of gastric acid secretion over 24 h. Vonoprazan fumarate (TAK-438, hereinafter referred to as "vonoprazan") is a new potassium-competitive acid blocker (P-CAB) developed to resolve the above limitations of conventional PPIs. Various physicochemical data have shown that vonoprazan has a high solubility and stability over a broad pH range in aqueous conditions. In addition, vonoprazan has a more potent and longer-lasting acid suppression effect than the conventional PPI, lansoprazole. Preclinical pharmacokinetic studies have shown that vonoprazan is accumulated and retained in the stomach for more than 24 h, even after it is eliminated from the plasma. From these findings, we propose that vonoprazan, which possesses a novel mode of action, can improve on the outcomes seen with conventional PPI-based treatments for acid-related diseases. This review project, including the publication of this article, was funded by Takeda Pharmaceutical Company Limited. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 17% |
| Researcher | 4 | 10% |
| Lecturer > Senior Lecturer | 3 | 7% |
| Professor > Associate Professor | 3 | 7% |
| Student > Bachelor | 3 | 7% |
| Other | 11 | 27% |
| Unknown | 10 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 20% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Arts and Humanities | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 6 | 15% |
| Unknown | 10 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2016.
All research outputs
#18,463,662
of 22,877,793 outputs
Outputs from Advances in Therapy
#1,635
of 2,353 outputs
Outputs of similar age
#260,405
of 345,199 outputs
Outputs of similar age from Advances in Therapy
#33
of 55 outputs
Altmetric has tracked 22,877,793 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,353 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,199 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.